Finch Therapeutics Group is a clinical-stage pharmaceutical company developing biological drugs that can be taken orally. Its main drug, CP101, is currently in Phase 3 clinical testing to treat recurring Clostridioides difficile infections and hepatitis B virus, while it's also developing three other products to treat Crohn’s disease, ulcerative colitis, and autism spectrum disorder. Finch Therapeutics was founded in 2014 and is located in Somerville, Massachusetts, with collaborative and licensing agreements with Takeda Pharmaceutical Company Limited, Skysong Innovations LLC, and the University of Minnesota.